Is BMS/AstraZeneca's Dapagliflozin More Than Just Another Oral Diabetes Drug?
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III results with metformin leave some disappointed, while another study hints of niche role in insulin-resistant patients.